This is what a topic and post looks like. As an administrator, you can edit the post's title and content.
To customise your forum, go to the Administrator Control Panel. You can modify all aspects of your forum there, including installation of third-party plugins.
Please share your comments and questions below. The full article can be found here
Please share your questions and comments on the guidance for the inclusion of real-world evidence and data in advertising pieces.
Expanding the approach to exclusivity claims
@Agency and @Manufacturer A new advisory has been posted on Exclusivity Claims for Indications. If you have any questions, please post below:
Good Afternoon @Manufacturer and @Agency
Summer has wrapped up and ARO is in full swing. Thank you to all our clients for all the great feedback and support as we launched this new service. Click here to see a round up of our Q3 activities.
Hello @Manufacturer and @Agency
Halfway into 2022 and ARO has launched. Here's what was new in Q2.
Good Morning @Agency and @Manufacturer
We hope everyone enjoyed their long weekend.
The Fee Calculator is now LIVE on the PAAB.ca homepage:
The calculator will help to estimate the fee for your APS submissions starting in July. You'll simply follow the steps to input your information as accurately as possible to obtain an estimate of the fee for you submission. It will also help you test your level of understanding of the coming ARO service based on the documents we’ve published.
Read through the instructions, play around with the calculator and let us know if you have any questions.
Please leave questions on this guidance below:
Hello @Agency and @Manufacturer
With winter behind us, here’s your first quarter review of activities at PAAB.
Enjoy.
@Manufacturer and @Agency
NEW: PAAB Advisory – Small Space Ads
PAAB would like to thank everyone who collaborated with us on this project, for their time and expertise in the development of this advisory, including:
A cross-functional team from Brightworks
Ramy AinMelk, Digital Lead, GSK Canada
A cross-functional team from GSW
Andrew Leeson, Director of Client Services, Ogilvy Health
Jonathan Wasserman, M.B.A, Portfolio Marketing Lead, Pfizer Canada Oncology
Sylvain Messier, M.Sc, Senior Brand Manager, Pfizer Canada Rare Disease
Representatives from Tank Worldwide
If you have any questions about this advisory, please post below.
@Agency and @Manufacturer
The PAAB has posted a new guidance on study durations as a results of our global benchmarking initiative and based on industry consultation. Please see the Guidance Regarding Duration of Clinical Trials Used as Reference Support in Advertising and post any questions you have regarding this document, below.
Please note that this guidance will go into effect April 18th. PAAB will not be accepting submissions with updated data prior to this date to ensure all companies have sufficient time to assess the changes.
If you have comments or questions about the PAAB Forum Quarterly Review or content you'd like to see in the next quarterly update, let us know below:
If you have comments or questions about the PAAB Forum Quarterly Review or content you'd like to see in the next quarterly update, let us know below:
Check out some of the top Digital Conference Myths we've seen to date.
If you have comments or questions on the Tag Report, please submit below:
Enter your comments on this document here:
Enter your comments or questions on this document here:
Enter your comments or questions for this document here:
